Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Jul 18, 2014; 5(3): 247-254
Published online Jul 18, 2014. doi: 10.5312/wjo.v5.i3.247
Published online Jul 18, 2014. doi: 10.5312/wjo.v5.i3.247
Bone anabolics in osteoporosis: Actuality and perspectives
Andrea Montagnani, Metabolic Bone Diseases Area, Department of Internal Medicine, Misericordia Hospital, 58100 Grosseto, Italy
Author contributions: Montagnani A solely contributed to this paper.
Correspondence to: Andrea Montagnani, MD, PhD, Metabolic Bone Diseases Area, Department of Internal Medicine, Misericordia Hospital, Via Senese, 169, 58100 Grosseto, Italy. montagnaniand@gmail.com
Telephone: +39-564-483165 Fax: +39-564-485330
Received: November 16, 2013
Revised: May 19, 2014
Accepted: May 29, 2014
Published online: July 18, 2014
Processing time: 245 Days and 7.3 Hours
Revised: May 19, 2014
Accepted: May 29, 2014
Published online: July 18, 2014
Processing time: 245 Days and 7.3 Hours
Core Tip
Core tip: The study of agents active on bone formation is the main objective in the treatment of severe osteoporosis. rhparathyroid hormone (rhPTH) decreases vertebral, but not nonvertebral, fractures. On the contrary, antagonists of Wnt-inhibitors, that exert their effects mostly through a bone remodeling-independent mechanism, open new perspectives to improve not only trabecular bone but also cortical bone, with potential positive effect also on nonvertebral fractures incidence. The perspective in osteoporosis treatment should be more effective and better tolerated therapies aimed at minimizing individually fractures risk.